Stem Cell Research


Decrease in CD10 (NEP) Expression in Non-Alzheimer’s Dementia Patients after SB Cells® Treatment

Monica Lui, Jonathan Tang, Wen Ying Lee, Xiao Chen, Lee Chen, Tina Zhang, Puning Cheng, Jessica Ding, Tom Flashman and James Wang.

Aims: Dementia is characterized by cognitive decline and memory loss, as well as impairment in short-term memory, long-term memory, and judgement. The cognitive deficits associated with dementia can interfere significantly with their social relationships and activities, as well as their occupational functioning. We believe that our SB cell® therapy may be the next step in treating non-Alzheimer's dementia. 

Presentation of Case: We describe four patients who have been diagnosed with non-Alzheimer's dementia and have experienced significant improvements in their memory, mood, cognitive functioning, and ability to do daily tasks after receiving our SB cells® treatment.

Discussion: Patients receiving our stem cell therapy showed a significant decrease in CD10 expression, a marker for NEP. It suggested that there may be a beneficial effect of pharmaceutical inhibition of cerebral NEP on learning and memory due to the accumulation of peptides other than Aβ degradable by NEP. 

Conclusion: Our study may validate the existence of peptides targeted by NEP that may improve learning and provide a promising avenue to the treatment of non-Alzheimer’s dementia. We hoped to continue investigating new patient cases to determine the potential CD10 has as a genetic marker of dementia.